Refractory Ewing Sarcoma: Clinical Trials

2 trials for Refractory Ewing Sarcoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed. 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 22Completed 2

Follow Refractory Ewing Sarcoma: new trials by email Literature Review of Refractory Ewing Sarcoma trials Research Report on Refractory Ewing Sarcoma

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma
Phase 2CompletedNational Cancer Institute (NCI)232018-08-132026-04-03
Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma
Linsitinib - Relapsed Ewing Sarcoma, Refractory Ewing Sarcoma
Phase 2CompletedUniversity of Oxford162014-03-012019-06-03

Narrower conditions

Sarcoma, Ewing (2)  ·  Ependymoma (1)  ·  Familial ependymoma (1)  ·  Glioma (1)  ·  Hepatoblastoma (1)  ·  Histiocytosis, Langerhans-Cell (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Medulloblastoma (1)  ·  Neuroblastoma (1)  ·  Neuroectodermal Tumors, Primitive, Peripheral (1)  ·  Osteosarcoma (1)  ·  Rhabdoid Tumor (1)  ·  Rhabdomyosarcoma (1)  ·  Sarcoma (1)  ·  Wilms Tumor (1)

Broader conditions

Neoplasms (2)  ·  Neoplasms by Histologic Type (2)  ·  Neoplasms, Bone Tissue (2)  ·  Neoplasms, Connective Tissue (2)  ·  Neoplasms, Connective and Soft Tissue (2)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)  ·  Female Urogenital Diseases (1)  ·  Female Urogenital Diseases and Pregnancy Complications (1)  ·  Genetic Diseases, Inborn (1)  ·  Hemic and Lymphatic Diseases (1)  ·  Histiocytosis (1)  ·  Immune System Diseases (1)  ·  Immunoproliferative Disorders (1)  ·  Kidney Diseases (1)  ·  Kidney Neoplasms (1)

Interventions

3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol (1)  ·  palbociclib (1)

Sponsors

National Cancer Institute (NCI) (1)  ·  University of Oxford (1)

Countries

France (1)  ·  Germany (1)  ·  Italy (1)  ·  Netherlands (1)  ·  Puerto Rico (1)  ·  United Kingdom (1)  ·  United States (1)

Top investigators

Andrew B Hassan, BMBCh FRCP (1)  ·  Rajen Mody (1)

Results publications

PMID 31401903, PMID 39298716

NIH funding

U10CA180886 (1)